ImmunityBio, Inc. (IBRX) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है San Diego, CA, United States. वर्तमान CEO हैं Richard Gerald Adcock.
IBRX के पास है IPO तिथि 2015-07-28, 671 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $8B.
ImmunityBio, Inc. is a clinical-stage biotechnology company headquartered in San Diego that develops immunotherapies and vaccines for cancer and infectious diseases. The company's pipeline includes advanced immunotherapy and cell therapy platforms, featuring antibody-cytokine fusion proteins, synthetic immunomodulators, natural killer cells, and T cell therapies, with multiple candidates in Phase II and III clinical trials for liquid and solid tumors such as bladder, pancreatic, and lung cancers, as well as viral pathogens including SARS-CoV-2 and HIV. ImmunityBio has established strategic partnerships with leading research institutions including the National Cancer Institute and collaboration or licensing agreements with multiple biotechnology and healthcare organizations to advance its therapeutic pipeline.
